Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5753066 | 0.84 | HTR2C (0.62) | HTR2CHTR2A | |
| Hydrochloric Acid SCHEMBL6087088 | 0.84 | HTR2C (0.61) | HTR2CHTR2A | |
| SCHEMBL5752415 | 0.82 | HTR2C (0.62) | HTR2CHTR2A | |
| SCHEMBL6841695 | 0.82 | HTR2C (0.67) | HTR2CHTR2A | |
| SCHEMBL7417566 | 0.81 | HTR2C (0.71) | HTR2CHTR2A | |
| SCHEMBL9050180 | 0.81 | HTR2C (0.64) | HTR2CHTR2A | |
| Hydrochloric Acid SCHEMBL6086611 | 0.81 | HTR2C (0.61) | HTR2CHTR2A | |
| SCHEMBL7419042 | 0.81 | HTR2C (1.00) | HTR2CHTR2A | |
| SCHEMBL8528454 | 0.81 | HTR2C (1.00) | HTR2CHTR2A | |
| SCHEMBL5751582 | 0.80 | HTR2C (0.77) | HTR2CHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7053108-B2 | Indoline compounds | LES LABORATOIRES SERVIER (FR) | 2006-05-30 | — | — | US | claimed |
| EP-1348704-B1 | Indole derivatives as 5-HT2C antagonists, process for their preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2006-05-17 | — | — | EP | claimed |
| US-20040192736-A1 | New indoline compounds | LAVIELLE GILBERT (FR) | 2004-09-30 | — | — | US | claimed |
| US-20030199555-A1 | Indoline compounds and to pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2003-10-23 | — | — | US | claimed |
| EP-1348704-A1 | Indole derivatives as 5-HT2C antagonists, process for their preparation and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2003-10-01 | — | — | EP | claimed |
| US-7053108-B2 | Indoline compounds | LES LABORATOIRES SERVIER (FR) | 2006-05-30 | — | — | US | disclosed |
| EP-1348704-B1 | Indole derivatives as 5-HT2C antagonists, process for their preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2006-05-17 | — | — | EP | disclosed |
| US-20040192736-A1 | New indoline compounds | LAVIELLE GILBERT (FR) | 2004-09-30 | — | — | US | disclosed |
| US-6759421-B2 | N-(3-PYRIDYL)-1,2-DIHYDRO-3H-BENZO(E)INDOLE-3-CARBOXAMIDE DERIVATIVES USEFUL AS A 5-HT2C ANTAGONIST | LES LABORATOIRES SERVIER (FR) | 2004-07-06 | — | — | US | disclosed |
| US-20030199555-A1 | Indoline compounds and to pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2003-10-23 | — | — | US | disclosed |
| EP-1348704-A1 | Indole derivatives as 5-HT2C antagonists, process for their preparation and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2003-10-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199555-A1 | Indoline compounds and to pharmaceutical compositions containing them | TPH1, IDO1, HTR3A | HTR2C 6/4885HTR2A 17/4885 |
| US-20040192736-A1 | New indoline compounds | TPH1, HTR3A, HTR1D | HTR2C 4/4885HTR2A 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.